{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:56:09Z","timestamp":1791251769277,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T00:00:00Z","timestamp":1451347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s40263-015-0305-4","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T09:22:16Z","timestamp":1451380936000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["The Benzodiazepine\u2013Dementia Disorders Link: Current State of Knowledge"],"prefix":"10.1007","volume":"30","author":[{"given":"Antoine","family":"Pariente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie Billioti","family":"de Gage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"B\u00e9gaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,29]]},"reference":[{"key":"305_CR1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3109\/13651500903447810","volume":"14","author":"J Donoghue","year":"2010","unstructured":"Donoghue J, Lader M. Usage of benzodiazepines: a review. Int J Psychiatry Clin Pract. 2010;14:78\u201387.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"5","key":"305_CR2","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/00000542-199005000-00024","volume":"72","author":"MM Ghoneim","year":"1990","unstructured":"Ghoneim MM, Mewaldt SP. Benzodiazepines and human memory: a review. Anesthesiology. 1990;72(5):926\u201338.","journal-title":"Anesthesiology"},{"issue":"2","key":"305_CR3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0301-0511(86)90081-5","volume":"23","author":"HV Curran","year":"1986","unstructured":"Curran HV. Tranquillising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol. 1986;23(2):179\u2013213.","journal-title":"Biol Psychol"},{"issue":"1","key":"305_CR4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000336710","volume":"2","author":"J Puustinen","year":"2012","unstructured":"Puustinen J, Nurminen J, Vahlberg T, Lyles A, Isoaho R, Raiha I, et al. CNS medications as predictors of precipitous cognitive decline in the cognitively disabled aged: a longitudinal population-based study. Dement Geriatr Cogn Dis Extra. 2012;2(1):57\u201368.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"3","key":"305_CR5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00004714-200206000-00009","volume":"22","author":"S Paterniti","year":"2002","unstructured":"Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol. 2002;22(3):285\u201393.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"305_CR6","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/gps.1811","volume":"22","author":"EJ Bierman","year":"2007","unstructured":"Bierman EJ, Comijs HC, Gundy CM, Sonnenberg C, Jonker C, Beekman AT. The effect of chronic benzodiazepine use on cognitive functioning in older persons: good, bad or indifferent? Int J Geriatr Psychiatry. 2007;22(12):1194\u2013200.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"305_CR7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","volume":"18","author":"MJ Barker","year":"2004","unstructured":"Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18(1):37\u201348.","journal-title":"CNS Drugs"},{"issue":"3","key":"305_CR8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/09540260500071863","volume":"17","author":"CI Neutel","year":"2005","unstructured":"Neutel CI. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry. 2005;17(3):189\u201397.","journal-title":"Int Rev Psychiatry"},{"issue":"7","key":"305_CR9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1532-5415.2000.tb04758.x","volume":"48","author":"M Egan","year":"2000","unstructured":"Egan M, Moride Y, Wolfson C, Monette J. Long-term continuous use of benzodiazepines by older adults in Quebec: prevalence, incidence and risk factors. J Am Geriatr Soc. 2000;48(7):811\u20136.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"305_CR10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4088\/JCP.08m04181","volume":"70","author":"FE Taragano","year":"2009","unstructured":"Taragano FE, Allegri RF, Krupitzki H, Sarasola DR, Serrano CM, Lon L, et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry. 2009;70(4):584\u201392.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"305_CR11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/gps.2535","volume":"26","author":"PB Rosenberg","year":"2011","unstructured":"Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry. 2011;26(4):364\u201372.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"12","key":"305_CR12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","volume":"288","author":"CG Lyketsos","year":"2002","unstructured":"Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475\u201383.","journal-title":"JAMA"},{"issue":"7","key":"305_CR13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/JGP.0b013e3181a65210","volume":"17","author":"CS Wu","year":"2009","unstructured":"Wu CS, Wang SC, Chang IS, Lin KM. The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data. Am J Geriatr Psychiatry. 2009;17(7):614\u201320.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"305_CR14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/JGP.0b013e3181e049ca","volume":"19","author":"CS Wu","year":"2011","unstructured":"Wu CS, Ting TT, Wang SC, Chang IS, Lin KM. Effect of benzodiazepine discontinuation on dementia risk. Am J Geriatr Psychiatry. 2011;19(2):151\u20139.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"305_CR15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ageing\/afn277","volume":"38","author":"R Lagnaoui","year":"2009","unstructured":"Lagnaoui R, Tournier M, Moride Y, Wolfson C, Ducruet T, Begaud B, et al. The risk of cognitive impairment in older community-dwelling women after benzodiazepine use. Age Ageing. 2009;38(2):226\u20138.","journal-title":"Age Ageing"},{"issue":"3","key":"305_CR16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0895-4356(01)00453-X","volume":"55","author":"R Lagnaoui","year":"2002","unstructured":"Lagnaoui R, Begaud B, Moore N, Chaslerie A, Fourrier A, Letenneur L, et al. Benzodiazepine use and risk of dementia: a nested case-control study. J Clin Epidemiol. 2002;55(3):314\u20138.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"305_CR17","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/jech-2011-200314","volume":"66","author":"J Gallacher","year":"2011","unstructured":"Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health. 2011;66(10):869\u201373.","journal-title":"J Epidemiol Community Health"},{"issue":"11","key":"305_CR18","doi-asserted-by":"crossref","first-page":"e49113","DOI":"10.1371\/journal.pone.0049113","volume":"7","author":"PL Chen","year":"2012","unstructured":"Chen PL, Lee WJ, Sun WZ, Oyang YJ, Fuh JL. Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. PloS One. 2012;7(11):e49113.","journal-title":"PloS One"},{"key":"305_CR19","doi-asserted-by":"crossref","first-page":"g5205","DOI":"10.1136\/bmj.g5205","volume":"349","author":"S Billioti de Gage","year":"2014","unstructured":"Billioti de Gage S, Moride Y, Ducruet T, Kurth T, Verdoux H, Tournier M, et al. Benzodiazepine use and risk of Alzheimer\u2019s disease: case\u2013control study. BMJ. 2014;349:g5205.","journal-title":"BMJ"},{"key":"305_CR20","doi-asserted-by":"crossref","first-page":"e6231","DOI":"10.1136\/bmj.e6231","volume":"345","author":"S Billioti de Gage","year":"2012","unstructured":"Billioti de Gage S, Begaud B, Bazin F, Verdoux H, Dartigues JF, Peres K, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345:e6231.","journal-title":"BMJ"},{"issue":"10","key":"305_CR21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40264-015-0319-3","volume":"38","author":"P Imfeld","year":"2015","unstructured":"Imfeld P, Bodmer M, Jick SS, Meier CR. Benzodiazepine use and risk of developing Alzheimer\u2019s disease or vascular dementia: a case-control analysis. Drug Saf. 2015;38(10):909\u201319.","journal-title":"Drug Saf"},{"issue":"1","key":"305_CR22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00002093-199803000-00002","volume":"12","author":"J Fastbom","year":"1998","unstructured":"Fastbom J, Forsell Y, Winblad B. Benzodiazepines may have protective effects against Alzheimer disease. Alzheimer Dis Assoc Disord. 1998;12(1):14\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"305_CR23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000115439","volume":"30","author":"M Fish","year":"2008","unstructured":"Fish M, Bayer AJ, Gallacher JE, Bell T, Pickering J, Pedro S, et al. Prevalence and pattern of cognitive impairment in a community cohort of men in South Wales: methodology and findings from the Caerphilly Prospective Study. Neuroepidemiology. 2008;30(1):25\u201333.","journal-title":"Neuroepidemiology"},{"issue":"5955","key":"305_CR24","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1126\/science.1180962","volume":"326","author":"JE Kang","year":"2009","unstructured":"Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005\u20137.","journal-title":"Science"},{"issue":"4","key":"305_CR25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00213-006-0446-8","volume":"188","author":"MZ Mintzer","year":"2006","unstructured":"Mintzer MZ, Kuwabara H, Alexander M, Brasic JR, Ye W, Ernst M, et al. Dose effects of triazolam on brain activity during episodic memory encoding: a PET study. Psychopharmacology. 2006;188(4):445\u201361.","journal-title":"Psychopharmacology"},{"issue":"5","key":"305_CR26","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0893-133X(01)00280-9","volume":"25","author":"MZ Mintzer","year":"2001","unstructured":"Mintzer MZ, Griffiths RR, Contoreggi C, Kimes AS, London ED, Ernst M. Effects of triazolam on brain activity during episodic memory encoding: a PET study. Neuropsychopharmacology. 2001;25(5):744\u201356.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"305_CR27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1073\/pnas.012467899","volume":"99","author":"R Sperling","year":"2002","unstructured":"Sperling R, Greve D, Dale A, Killiany R, Holmes J, Rosas HD, et al. Functional MRI detection of pharmacologically induced memory impairment. Proc Natl Acad Sci USA. 2002;99(1):455\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"305_CR28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0960-894X(02)00909-5","volume":"13","author":"I Churcher","year":"2003","unstructured":"Churcher I, Ashton K, Butcher JW, Clarke EE, Harrison T, Lewis HD, et al. A new series of potent benzodiazepine gamma-secretase inhibitors. Bioorg Med Chem Lett. 2003;13(2):179\u201383.","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"305_CR29","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2174\/156802611795860942","volume":"11","author":"BP Imbimbo","year":"2011","unstructured":"Imbimbo BP, Giardina GA. Gamma-secretase inhibitors and modulators for the treatment of Alzheimer\u2019s disease: disappointments and hopes. Curr Top Med Chem. 2011;11(12):1555\u201370.","journal-title":"Curr Top Med Chem"},{"issue":"4","key":"305_CR30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med. 2013;369(4):341\u201350.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"305_CR31","first-page":"169","volume":"152","author":"PC May","year":"1993","unstructured":"May PC, Robison PM. GYKI 52466 protects against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures. Neurosci Lett. 1993;152(1\u20132):169\u201372.","journal-title":"Neurosci Lett"},{"issue":"24","key":"305_CR32","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1212\/WNL.0b013e3181e3966e","volume":"74","author":"JL O\u2019Brien","year":"2010","unstructured":"O\u2019Brien JL, O\u2019Keefe KM, LaViolette PS, DeLuca AN, Blacker D, Dickerson BC, et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology. 2010;74(24):1969\u201376.","journal-title":"Neurology"},{"issue":"12","key":"305_CR33","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.neurobiolaging.2006.08.008","volume":"28","author":"A Hamalainen","year":"2007","unstructured":"Hamalainen A, Pihlajamaki M, Tanila H, Hanninen T, Niskanen E, Tervo S, et al. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging. 2007;28(12):1889\u2013903.","journal-title":"Neurobiol Aging"},{"issue":"8","key":"305_CR34","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/nm.3639","volume":"20","author":"S Jo","year":"2014","unstructured":"Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M, Woo DH, et al. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer\u2019s disease. Nat Med. 2014;20(8):886\u201396.","journal-title":"Nat Med"},{"issue":"9","key":"305_CR35","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1523\/JNEUROSCI.1203-12.2013","volume":"33","author":"C Martinez-Cue","year":"2013","unstructured":"Martinez-Cue C, Martinez P, Rueda N, Vidal R, Garcia S, Vidal V, et al. Reducing GABAA alpha5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome. J Neurosci. 2013;33(9):3953\u201366.","journal-title":"J Neurosci."},{"key":"305_CR36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.neuroscience.2014.01.063","volume":"265","author":"Y Hatayama","year":"2014","unstructured":"Hatayama Y, Hashimoto T, Kohayakawa H, Kiyoshi T, Nakamichi K, Kinoshita T, et al. In vivo pharmacological characterization of AC-3933, a benzodiazepine receptor partial inverse agonist for the treatment of Alzheimer\u2019s disease. Neuroscience. 2014;265:217\u201325.","journal-title":"Neuroscience"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0305-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-015-0305-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0305-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:26Z","timestamp":1559490086000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-015-0305-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,29]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1007\/s40263-015-0305-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,29]]}}}